Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCENT-2: DN-101 (calcitriol) + docetaxel in androgen-independent prostate cancer
DRKS00003880Phase 3Terminated
- Sponsor
- Novacea
- Start
- Apr 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) comparing DN-101 (calcitriol) + docetaxel with Docetaxel control (2 arms). Started Apr 2012; status: terminated.
02
Drugs
calcitrioldocetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on DRKS00003880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00003880.